Vical Inc of the USA has announced that Centocor, a Johnson & Johnsoncompany, has expanded its earlier license and option agreement to use Vical's naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer.
Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future. The agreement does not change Vical's forecast for a net loss of $28-$32 million for 2002, the company said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze